CADL · NASDAQ · Biotechnology

Candel Therapeutics (CADL)

Develops viral immunotherapies for solid tumors through adenovirus and HSV platforms.

$11.81
vs last close−0.04 (−0.34%)

Something off on this page? Send us feedback.

Next report
Nov 12, 26
estimated · in 50 days
EPS estimate
−$0.30
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.40$0.13−$0.09−$0.21−$0.54−$0.14−$0.52Pending
Estimate−$0.23−$0.24−$0.17−$0.17−$0.24−$0.22−$0.24−$0.30
Surprise−73.9%+154.2%+47.1%−23.5%−125.0%+36.4%−118.6%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

HistoryUpcoming

Date / PeriodEstimateReportedSurprise
Dec 2027−$0.35
Sep 2027−$0.48
Jun 2027−$0.37
Mar 2027−$0.35
Dec 2026−$0.33
Nov 2026−$0.30
Aug 2026−$0.24−$0.52−118.6%
May 2026−$0.22−$0.14+36.4%
Mar 2026−$0.24−$0.54−125.0%
Nov 2025−$0.17−$0.21−23.5%
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Sep 2021
Jul 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.

Date / PeriodEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Dec 2027−$0.35$14.9M
Sep 2027−$0.48$0
Jun 2027−$0.37$2.5M
Mar 2027−$0.35$0
Dec 2026−$0.33$0
Nov 12, 2026−$0.30$0
Aug 13, 2026−$0.24−$0.52−118.6%+10.5%
May 14, 2026−$0.22−$0.14+36.4%−0.3%
Mar 12, 2026−$0.24−$0.54−125.0%−6.2%
Nov 13, 2025−$0.17−$0.21−23.5%−6.3%
Aug 14, 2025
May 13, 2025
Mar 13, 2025
Nov 14, 2024
Aug 13, 2024
May 14, 2024
Mar 28, 2024
Nov 9, 2023
Aug 10, 2023
May 11, 2023
Mar 30, 2023
Nov 10, 2022
Aug 5, 2022
May 12, 2022
Mar 29, 2022
Nov 12, 2021
Sep 8, 2021
Jul 28, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020

The latest year is open to everyone — the 22 quarters behind it read with an account.